Association of rs10204525 genotype GG and rs2227982 CC combination in programmed cell death 1 with hepatitis B virus infection risk

Chunhong Huang, MD, TaiTian Ge, MD, Caixia Xia, MD, Wei Zhu, BS, Lichen Xu, MD, Yunyun Wang, MD, Fengtian Wu, MD, Feifei Liu, MD, Min Zheng, PhD, Zhi Chen, PhD

Abstract
Single nucleotide polymorphism (SNP) of programmed cell death 1 (PD-1) was reported associated with hepatitis B virus (HBV) infection, but the SNP sites studied were limited. Whether the combination of 2 or more SNP sites could better represent the relationship between PD-1 SNP and HBV infection was not studied.

Eight hundred ninety-eight HBV-infected patients (222 asymptomatic carriers [AsC], 276 chronic hepatitis B, 105 acute-on-chronic liver failure, and 295 liver cirrhosis) and 364 healthy controls of South China were enrolled in this study. Four PD-1 SNPs (rs10204525, rs2227982, rs41386349, and rs36084323) were selected and detected by TaqMan probe. The frequency of allele, genotype, and combination of different SNPs were compared between different groups.

For allele frequency analysis, G allele of rs10204525 was protective factor (odds ratio (OR) = 0.823, 95% confidence interval (CI) = 0.679–0.997, \( P = 0.046 \)) and T allele of rs2227982 was predisposing factor (OR = 1.231, 95% CI = 1.036–1.463, P = 0.018) in HBV infection. When analysis in genotype frequency, the genotype GG of rs10204525 and CC of rs2227982 were protective factor of HBV infection. Combination of rs10204525 GG and rs2227982 CC was potent protective factor of HBV infection (OR = 0.552, 95% CI = 0.356–0.857, P = 0.007) and was also associated with lower HBV load (OR = 0.201, 95% CI = 0.056–0.728, P = 0.008) in AsC. The 4 SNP sites were not associated with progression of HBV-related liver disease.

Rs10204525 and rs2227982 of PD-1 associate with HBV infection and combination of the 2 SNP sites can better predict host susceptibility in HBV infection.

Abbreviations: ACLF = acute-on-chronic liver failure, ALT = alanine transaminase, AsC = asymptomatic carrier, CHB = chronic hepatitis B, EDTA = ethylene diamine tetraacetic acid, ESR1 = estrogen receptor alpha, HBSAg = hepatitis B surface antigen, HBV = hepatitis B virus, HC = health control, HLA-DR = human leukocyte antigen-DR, INR = international normalized ratio, LC = liver cirrhosis, MAF = minor allele frequency, MBP = mannose-binding protein, PD-1 = programmed cell death 1, SNP = single nucleotide polymorphism, TBIL = total bilirubin.

Keywords: HBV, PD-1, single nucleotide polymorphism, susceptibility

1. Introduction
Hepatitis B is one of the most common infectious diseases worldwide. Data from World Health Organization (WHO) website shows that 240 million individuals are infected with hepatitis B virus (HBV) (WHO 2016; http://www.who.int/mediacentre/factsheets/fs204/en/), and over 0.68 million death every year due to complications of hepatitis B, such as cirrhosis and liver cancer. It is a multistage process from asymptomatic carrier (AsC) to chronic hepatitis B (CHB) and even cirrhosis. Researches reveal that host’s immune system, especially virus-specific T cells, plays an important role during the process.

Programmed cell death 1 (PD-1) is known as co-inhibitory regulator of T-cell responses. T cells with high PD-1 expression are in exhaustion with decreased cytotoxic function, lower interferon-\( \gamma \) secretion, and reduced proliferating potential. HBV-specific T cells in CHB patients exhibit higher PD-1 expression, in comparison with healthy individuals, which was associated with impaired virus clearance. PD-1 blockage is capable to restore T cell functions and promote antiviral immunity.

Host genetic component is one of the key factors that lead to persistent HBV infection. Variants of host genes, such as mannose-binding protein, estrogen receptor alpha, and human leukocyte antigen-DR affect the process of hepatitis B and HBV clearance. Single nucleotide polymorphism (SNP) is a kind of genetic variant which is the mutation in individual bases
scattered throughout the genome. SNP influence the protein function that was encoded by the same gene. As PD-1 is important immune regulatory molecules in HBV infection, its genetic polymorphism may influence outcome of HBV infection. Although the association of genetic polymorphism of PD-1 with HBV has been investigated previously, the SNP sites they analyzed were limited and more other sites were waiting to be tested. What’s more, most investigations only studied the SNP sites separately. As each SNP site had its own influence, the combination of them may be more powerful in elucidating the relationship between genetic factor of PD-1 and HBV infection. Also, the researches mainly focused on the influences on HBV associated cancer and the influence on acute-on-chronic liver failure (ACLF) was not reported. To further clarify the relationship between PD-1 polymorphism and HBV infection, we selected 4 PD-1 SNPs (rs10204525, rs2227982, rs41386349, rs36084323), and performed a retrospective case-control study.

2. Material and methods

2.1. Ethics statement

The study is approved by the ethics committee of Zhejiang University, China. The written informed consent is obtained from each participant. The study is carried out in accordance with the guidelines of the 1975 Declaration of Helsinki.

2.2. Study participants

This study recruited 898 HBV-infected patients at the First Affiliated Hospital, Zhejiang University from March, 2015 to January, 2016 and 364 health controls (HCs) from the physical examination center of the hospital during the time. Patients with positive serum hepatitis B surface antigen (HBsAg) or HBV DNA were diagnosed as HBV infection and were classified into 4 groups according to the Guideline of Prevention and Treatment for CHB [17]: 222 AsC, 276 CHB, 295 liver cirrhosis (LC), and 105 ACLF. AsC was diagnosed according to the criteria described previously [18]. CHB was diagnosed as seropositive HBsAg or HBV DNA, with consistently or recurrently high level of alanine transaminase (ALT) for more than 6 months. LC was diagnosed if any sign of cirrhosis was found by imaging examination. ACLF was diagnosed if serum total bilirubin (TBIL) was higher than 10 times of normal upper limit (171 μM) or increases more than 17.1 μM/d, and prothrombin time activity ≤40% (or international normalized ratio ≥1.5).

The patients were excluded with the following diseases:

1) hepato-carcinoma;
2) other hepatitis virus infections;
3) other diseases which can lead to immune system disorder such as auto-immune diseases and cancer;
4) major organ dysfunction like heart, lung.

The blood sample (approximately 2 mL) was collected from the filtered participants. All the procedure above was shown in Figure 1.

2.3. DNA extraction

Whole blood samples were collected into ethylene diamine tetraacetic acid coated tubes and stored at −80°C. Genomic DNA was extracted from whole blood using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instruction and then stored at −80°C.

2.4. SNP selection and genotyping

Candidate SNP sites of PD-1 were collected to HapMap Chinese population data. The SNPs with a minor allele frequency (MAF) >0.01 were included. Finally, 4 PD-1 SNP sites were included in this study. The details of the SNP sites were shown in Table 1. The SNPs were genotyped by TaqMan probe (Applied Biosystems, Foster City).

2.5. Statistical analysis

At first, Hardy–Weinberg equilibrium (HWE) was tested for each SNP by Pearson χ² test. Then, we compared the distribution of demographic characteristics of each SNP between different groups. For analysis of allele and genotype, the Pearson χ² test (or Fisher exact test) were used. Multi-factor logistic regression analysis was selected if the 2 groups have different distribution of age and sex. When comparing the genotype frequency of each SNP between different groups, we used the following gene models: (i) “A” was major allele and “a” was minor) dominant gene model (Aa + aa vs AA), recessive gene model (aa vs AA + Aa), and additive gene model (aa vs Aa vs AA), codominant gene model (aa vs AA and Aa vs AA). All the statistical analyses were carried out using SPSS 20.0 software (SPSS Inc., Chicago, IL). The difference between 2 groups was considered statistically significant if P <0.05 (2-sided). Odds ratios (ORs) and 95% confidence intervals (CIs) were used to show the degree of association between groups.

3. Results

3.1. Clinical features of the study participants

The demographics and clinical characteristics of HCs, HBV patients and its subgroups including AsC, CHB, ACLF, and LC, were shown in Table 2. The average age was 42.37 ± 12.44 in the HBV group and was 40.81 ± 13.76 in HCs. The HBV patients included 637 (70.94%) males and 261 (29.06%) females. The HCs consisted of 235 (64.56%) males and 129 (35.44%) females. No significant differences were found in age and gender between HBV patients and controls (P >0.05, data not shown). But the distribution of age and gender in the 4 subgroups was not equal (P <0.05, data not shown). ALT, aspartate aminotransferase, TBIL, and albumin in different groups changed, as they indicating the liver function which changed with the disease progression.

3.2. Genotypic and allele distribution

The genotypic and allele distribution of the 4 SNP sites were shown in Table S1, http://links.lww.com/MD/D203. The MAFs of 4 PD-1 SNPs were as follows: rs10204525, 0.265; rs2227982, 0.540; rs41386349, 0.216 (Table 1). The observed values of every SNP genotypes showed no significant differences when compared with expected values in HCs (all P >0.5, Table S2, http://links.lww.com/MD/D203), therefore the genotypes distribution of the 4 SNPs was in HWE.

3.3. Rs10204525 and rs2227982 polymorphisms were associated with HBV infection

The results of association between PD-1 polymorphisms and HBV susceptibility were shown in Table 3. In the 4 PD-1 SNPs,
rs10204525 and rs2227982 polymorphisms were associated with HBV infection. For allele frequency, the minor allele G of rs10204525 was protective factor and T of rs2227982 predisposing factor with HBV susceptibility (OR = 0.823, 95% CI = 0.679–0.997, P = .046; OR = 1.231, 95% CI = 1.036–1.463, P = .018, respectively).

Then the genotype was analyzed. For rs10204525, subjects carrying genotype GG had a significantly decreased risk of getting infected with HBV (recessive gene model: OR = 0.614, 95% CI = 0.401–0.940, P = .024; codominant gene model (GG:AA): OR = 0.594, 95% CI = 0.383–0.922, P = .019). For rs2227982, the TT and CT frequency of HBV patients was significantly higher than that of HCs (dominant gene model: OR = 1.490, 95% CI = 1.120–1.980, P = .006; codominant gene model (TT:CC): OR = 1.467, 95% CI = 1.081–1.991, P = .014; codominant gene model (CT:CC): OR = 1.531, 95% CI = 1.090–2.151, P = .014). From all the results above, the genotype GG of rs10204525 and CC of rs2227982 were protective factors of HBV infection.

The polymorphisms of rs41386349 and rs36084323 were not related to HBV infection. The allele frequency of minor allele T of rs41386349 and G of rs36084323 in HBV patients showed no significant difference compared with HC (OR = 1.053, 95% CI = 0.853–1.299, P = .623; OR = 0.871, 95% CI (0.730–1.038), P = .122, respectively). As for the genotype frequency, 2 polymorphism sites still showed no significant between HBV patients and HC (all P > .05).

3.4. Combination of rs10204525 GG and rs2227982 CC was associated with lower HBV infection risk
As rs10204525 G and rs2227982 C were both protective factors of HBV infection, we tried to analyze whether their combination
could cooperate in defending HBV infection. As shown in Table 3, recessive model could well represent the difference between wild-type and mutation of rs10204525 on HBV infection, so we divided the 3 genotypes AA AG and GG into AA + AG group and GG group. Genotypes of rs2227982 were divided into CC group and CT + TT group, following the same rule. As a result, there were 4 combinations of the groups between the 2 SNPs, as shown in Table S3, http://links.lww.com/MD/D203, which also displayed the distributions of the 4 combinations in different subject groups.

### Table 1

Locations and allele frequencies of SNPs.

| Polymorphism site | Location | Distance to next (bp) | Gene sequence | Minor allele frequency (%) |
|-------------------|----------|----------------------|---------------|---------------------------|
| rs10204525        | 3'UTR    |                      | cctagggcaccctag/cggagact | G (26.5) |
| rs2227982         | Exon 5   | 1112                 | agagggcaccctag/tggagctcctg | T (64.9) |
| rs41386349        | Intron 4 | 416                  | ggagggcaccctag/tggagctcctg | T (21.6) |
| rs36084323        | Promoter | 7747                 | gaaggggagggctag/a/ggaaggc | G (39.0) |

SNPs = singlenucleotide polymorphisms.

### Table 2

Clinical demographics of the groups.

|            | HC  | HBV patients | AsC | CHB | ACLF | LC  |
|------------|-----|--------------|-----|-----|------|-----|
| No. of patients | 364 | 898          | 222 | 276 | 105  | 295 |
| Age (years)  | 40.81±13.76 | 42.37±12.44 | 36.17±9.35 | 37.17±10.17 | 46.35±12.4 | 50.53±11.32 |
| Sex (male %) | 235(64.56%) | 637(70.94%) | 119(53.60%) | 205(74.28%) | 88(83.81%) | 219(74.24%) |
| ALT (U/L)    | 18.22±12.31 | 143.44±281.72 | 22.82±8.99 | 22.82±181.62 | 227.36±222.76 | 64.68±120.84 |
| AST (U/L)    | 20.50±12.96 | 93.84±150.16 | 22.40±5.60 | 245.12±355.85 | 227.36±181.62 | 64.45±84.66 |
| TBIL (µmol/L)| 12.18±13.85 | 93.13±148.26 | 12.56±6.49 | 58.08±90.08 | 351.73±160.04 | 93.07±141.55 |
| ALB (g/L)    | 44.77±12.53 | 39.35±8.15    | 47.06±3.08 | 41.26±6.56 | 32.40±4.44 | 33.52±6.11 |

ACLF = acute-on-chronic liver failure, ALB = serum albumin, ALT = alanine aminotransferase, AsC = asymptomatic carrier, AST = aspartate aminotransferase, CHB = chronic hepatitis B, HBV = hepatitis B virus, HC = health control, LC = liver cirrhosis, TBIL = total bilirubin.

### Table 3

Genotype and allele distribution of PD-1 SNPs in HBV patients and health controls.

| SNP       | Test | OR (95% CI)       | P    |
|-----------|------|-------------------|------|
| rs10204525 (A>G) | Allelic | 0.823(0.679–0.997) | .046 |
|           |       | Dominant          | 0.852(0.667–1.088) | .198 |
|           |       | Recessive         | 0.614(0.401–0.940) | .024 |
|           |       | Additive          | –    | .065 |
|           | Codominant | Reference   | Reference |
| rs2227982 (C>T) | Allelic | 1.231(1.036–1.463) | .018 |
|           |       | Dominant          | 1.490(1.120–1.980) | .006 |
|           |       | Recessive         | 1.179(0.899–1.548) | .234 |
|           |       | Additive          | –    | .022 |
|           | Codominant | Reference   | Reference |
| rs41386349 (C>T) | Allelic | 1.531(1.090–2.151) | .014 |
|           |       | Dominant          | 1.467(1.081–1.991) | .014 |
|           |       | Recessive         | 0.935(0.513–1.702) | .825 |
|           |       | Additive          | –    | .739 |
|           | Codominant | Reference   | Reference |
| rs36084323 (A>G) | Allelic | 0.870(0.730–1.038) | .122 |
|           |       | Dominant          | 0.853(0.663–1.096) | .214 |
|           |       | Recessive         | 0.822(0.600–1.126) | .222 |
|           |       | Additive          | –    | .329 |
|           | Codominant | Reference   | Reference |

CI = confidence interval, HBV = hepatitis B virus, OR = odds ratio, PD-1 = programmed cell death 1, SNP = single nucleotide polymorphism.
Combination of rs10204525 AA + AG and rs2227982 CC and combination of rs10204525 GG and rs2227982 TT/CT (P = .097 and P = .457, respectively) (Table 4). Combination of rs10204525 GG and rs2227982 CC showed significantly lower frequency in HBV patients (OR = 0.552, 95% CI = 0.356–0.857, P = .007), which meant this combination was associated with lower HBV infection risk.

When dividing HBV patients into subgroups, we found that combination of rs10204525 GG and rs2227982 CC showed coordinated lower frequency in AsC (OR = 0.305, 95% CI = 0.139–0.671, P = .002), CHB (OR = 0.401, 95% CI = 0.204–0.788, P = .006) but not LC (OR = 0.858, 95% CI = 0.507–1.453, P = .569) compared with HC.

### 3.5. Combination of rs10204525 GG and rs2227982 CC were associated with lower HBV load in AsC

Subjects of AsC were classified into 2 group, HBV undetectable and HBV detectable. Allele and genotype analysis of rs10204525 and rs2227982 were carried out in AsC about the influence on HBV load and the correlation was poor (Table S4, http://links.lww.com/MD/D203). When the combination was taken into account, combination of rs10204525 GG and rs2227982 CC had lower percentage in HBV detectable group (OR = 0.201, 95% CI = 0.036–0.728, P = .008) (Table 5).

### 3.6. Association of PD-1 polymorphisms with disease progression

We performed the following 3 comparisons: CHB versus AsC, LC versus CHB, and ACLF versus CHB, to unveil the relation between PD-1 variants and progression of HBV-related liver diseases (Table 6). LC had higher rs10204525 G allele compared with CHB (P = .033). T allele of rs41386349 showed lower frequency in CHB compared with AsC (P = .042). As for comparison of rs41386349 genotype between LC versus CHB, dominant model analysis displayed that TT was protective factor of LC (OR = 0.605, 95% CI = 0.410–0.891, P = .011), but when in codominant model, CT showed predisposing factor on LC (OR = 2.495, 95% CI = 1.020–5.784, P = .045) and TT had the same frequency with CC (P = .166).

### 4. Discussion

In this study, we found T allele of rs2227982 was suggested to be a predisposition factor of HBV infection. Consistent with previous studies, G allele on rs10204525 site was a protective factor in HBV infection.[15,16] We also proved that combination of rs10204525 GG with rs2227982 CC showed better protection from HBV infection and the combination also related with a lower HBV load in AsC. In all, the results above further show that genetic variants of PD-1 play roles in HBV infection and combination of SNP sites are more efficient in defending HBV infection. The results contribute to illustrating the way host genetic factors influence HBV infection and provide a method of combing SNPs together to predict the risk of HBV infection and outcome.

Statistics data on the WHO website (http://www.who.int/mediacentre/factsheets/fs204/en/) shows that there is high prevalence in East Asian with a 5% to 10% CHB in adult population and only less than 1% of Western Europe and North America is chronically infected. Brazilian families of Asian origin have a higher occurrence of HBsAg (P < .0001) than of Western origin,[19] which meant ethnic factors may influence HBV infection. According to data on the 1000 Genomes and HapMap, the frequency of protective rs10204525 G is much lower in Chinese (0.267 for Han Chinese in Beijing and 0.879 for British in England and Scotland) and the predisposing factor rs2227982 T is higher (0.495 for Han Chinese in Beijing and 0.006 for British in England and Scotland). These may explain why China has a high rate of HBV infection in host genetic aspect.

T cells with higher PD-1 expression are in exhaustion and blocking PD-1 can restore it and promote antiviral immunity.[13,8,9] It has also been reported that a genetic variant (rs11568821) may affect PD-1 mRNA level by change the binding affinity of RUNX (a transcriptional factor of PD-1).[20] Combining these previous conclusions with our work, we believe that the genetic variants, rs2227982 and rs10204525 of PD-1 influence patients’ HBV susceptibility and disease progression by regulating the expression and function of PD-1.

### Table 4

| rs10204525 | rs2227982 | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) |
|------------|-----------|---------|-------------|---------|-------------|---------|-------------|---------|-------------|
| AA + AG    | TT or CT  | Reference | Reference   | Reference | Reference   | Reference | Reference   | Reference | Reference   |
| AA + AG    | CC        | .097    | 0.749 (0.532–1.055) | .032    | 0.575 (0.345–0.979) | .865    | 0.964 (0.630–1.4174) | .263    | 0.777 (0.500–1.209) |
| GG         | TT or CT  | .547    | 1.857 (0.216–15.966) | .808    | 1.413 (0.086–22.727) | .446    | 2.472 (0.223–27.447) | .471    | 2.352 (0.212–26.113) |
| GG         | CC        | .007    | 0.552 (0.356–0.857) | .002    | 0.305 (0.139–0.671) | .006    | 0.401 (0.204–0.788) | .569    | 0.858 (0.507–1.453) |

AQLF = acute-on-chronic liver failure, AsC = asymptomatic carrier, CHB = chronic hepatitis B, CI = confidence interval, HBV = hepatitis B virus, HC = health control, LC = liver cirrhosis, OR = odds ratio.

### Table 5

| rs10204525 | rs2227982 | HBV undetectable | HBV detectable | P | OR |
|------------|-----------|------------------|----------------|---|----|
| Other      | Other     | 96               | 110            |   |    |
| GG         | CC        | 13               | 3              | .008 | 2.010 (0.056–0.728) |

HBV = hepatitis B virus, OR = odds ratio.
Rs2227982, which was associated with the risk and disease progression of ankylosing spondylitis and breast cancer in previous reports, was revealed to be relevant to HBV susceptibility in our study. Rs2227982 locates in the 5th exon of PD-1 and its polymorphism leads to a nonsynonymous mutation (Ala to Val) during protein synthesis, which may influence the function of PD-1. The G allele of rs10204525 was a protective factor in HBV infection, which was consistent with the previous reports, was revealed to be relevant to HBV infection. G allele of rs10204525 was a protective factor in HBV infection. As 1 SNP site could not well represent the influence of PD-1 genetic variants in HBV infection, we analyzed the genotype combination of rs10204525 and rs2227982. Results revealed that the combination of rs10204525 GG and rs2227982 CC were more efficient in reducing HBV infection risk and HBV load compared with GG or CC alone. This may show a way by integrating different SNP sites to fully elucidate the susceptibility of HBV infection from host genetic perspective. The integration also provide evidence for the doctor in individually treating HBV patients.

Still, more works are ongoing to be done. First, the population tested was limited to Eastern China, and more subjects from other populations should be included to verify the result. Second, we have revealed the potential association between the selected SNPs and HBV infection at this step, on the next step, we will explore the molecular mechanism underling the relationship, especially on rs2227982. Third, we can select a series of representative SNPs on genes which in fluence susceptibility and progression of HBV and make a rating scale to evaluate individual’s outcome on getting HBV infection from the host perspective.
Author contributions

Data curation: Chunhong Huang, Tianxian Ge, Caixia Xia, Feifei Liu.
Formal analysis: Chunhong Huang, Caixia Xia, Fengtian Wu.
Investigation: Caixia Xia.
Methodology: Chunhong Huang, Zhi Chen.
Project administration: Chunhong Huang.
Resources: Wei Zhu.
Software: Lichen Xu, Yunyun Wang.
Supervision: Min Zheng, Zhi Chen.
Writing – original draft: Chunhong Huang.
Writing – review and editing: Chunhong Huang, Zhi Chen.
Zhi Chen orcid: 0000-0002-0488-1502.

References

[1] Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016;20:607–28.
[2] GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2015;385:117–71.
[3] Bertolotti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol 2016;64(1 Suppl):S71–83.
[4] Bertolotti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1734–44.
[5] Golden-Mason L, Palmer B, Klarcquist J, et al. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8 + T cells associated with reversible immune dysfunction. J Virol 2007;81:9249–58.
[6] Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008;45:963–70.
[7] Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology (Baltimore, Md) 2008;48:759–69.
[8] Yang ZS, Hao YH, Zhang EJ, et al. CD8 family of receptors on T cells in chronic HBV infection: expression characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep 2016;14:1107–16.
[9] Liu J, Zhang S, Hu Y, et al. Targeting PD-1 and Tim-3 pathways to reverse CD8 T cell exhaustion and enhance ex vivo T cell responses to autologous dendritic tumor vaccines. J Immunother (Hagerstown, Md: 1997) 2016;39:171–80.
[10] Thursz M. Genetic susceptibility in chronic viral hepatitis. Antivir Res 2001;52:113–6.
[11] Thomas HC, Foster GR, Sumiya M, et al. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet (London, England) 1996;348:1417–9.
[12] Deng G, Zhou G, Zhai Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology (Baltimore, Md) 2004;40:318–26.
[13] Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:391–5.
[14] Liao J, Zhang Q, Liao Y, et al. Association of T cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection. PLoS One 2014;9:e98280.
[15] Zhang GY, Liu ZW, Duan SQ, et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol 2010;71:1209–13.
[16] Li Z, Li N, Zhu Q, et al. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infect Genet Evol 2013;14:240–6.
[17] Chinese Society of Hepatology. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi 2011;32:13–24.
[18] Chen F, He JL, Zheng M, et al. Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection. J Viral Hepat 2013;20:566–74.
[19] Carrihlo R, Omo-Nita SK, Cardoso RA, et al. A prospective study of hepatitis B virus carriers in patients with chronic HBV infection from Brazilian families of Western and Asian origin. Braz J Med Biol Res 2005;38:1399–408.
[20] Prokunina L, Castillejo-Lopez C, Oberg F, et al. Regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666–9.
[21] Chen S, Li Y, Deng C, et al. The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review. Rheumatol Int 2016;36:33–44.
[22] Ren HT, Li YM, Wang XJ, et al. PD-1 rs2227982 polymorphism is associated with the decreased risk of breast cancer in Northwest Chinese women: a hospital-based observational study. Medicine (Baltimore) 2016;95:e5760.
[23] Liu S, Huang S, Chen F, et al. Genomic analyses from non-invasive prenatal testing reveal genetic associations, patterns of viral infections, and Chinese population history. Cell 2018;175:347–59.e14.
[24] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[25] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[26] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[27] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[28] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[29] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.
[30] Zhang G, Li N, Zhang P, et al. PD-1 mRNA expression is associated with clinical and viral profile and PD1 3‘-untranslated region polymorphism in patients with chronic HBV infection. Immunol Lett 2014;162:212–6.